High-Quality Activin A for the Differentiation of iPSCs into Pancreatic Islet Cells

Credit: ACRO Biosystems

Diabetes is one of the fastest growing chronic diseases globally and a leading cause of various serious health issues, including cardiovascular disease, blindness, renal failure, and amputation. One promising treatment avenue is the transplantation of fully differentiated islet cells derived from stem cells. On September 25th, 2024, a landmark study published in Cell by Dr. Deng Hongkui’s team at Peking University represents a significant milestone in diabetes treatment. For the first time, researchers successfully transplanted chemically induced pluripotent stem cell-derived (CiPSC) islets into a patient with Type 1 diabetes, leading to insulin independence. This achievement could pave the way for new advances in regenerative medicine and revolutionize Type 1 diabetes treatment.

We eagerly anticipate further advancements in stem cell therapies that could improve the lives of millions living with diabetes. With a robust cell culture platform and GMP quality management system, we are pleased to announce the launch of Human Activin A / INHBA Protein, premium grade (Cat. No. ACA-H5314) which can support large-scale differentiation of stem cell differentiation into endoderm, including beta islet cells and other cell types, accelerating your research progress of stem cell therapy.

GMP Human Activin A / INHBA Protein (Cat. No. GMP-ACAH37) is coming soon!

Product Features:

Facilitate stem cell differentiation into endoderm, including beta islet cells and other cell types.
Ensure reliable, large-scale manufacturing capabilities.
Achieve cost efficiency, saving up to 50%.

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed for discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated to innovation to simplify and accelerate the development of new, better, and more affordable medicine. Our way of addressing challenges in biologics development is to offer a comprehensive array of tools and solutions designed for each development phase. Starting from discovery and development and moving beyond commercialization, we strive to deliver high-quality solutions that support each step of the development process. This means bringing together innovation and technology through product development and collaborations to help our customers achieve translatable results in the clinic and beyond.

Interested in seeing more content from ACROBiosystems ?

Discover all their latest news, webinars, products and more by clicking the link below.

Chosen for You